Becker R C
Thrombosis Research Center, University of Massachusetts Medical School, Worcester.
Cardiology. 1991;79(1):49-63. doi: 10.1159/000174860.
Platelets contribute to normal hemostasis by adhering to subendothelial tissues after vascular damage has taken place and then recruiting additional platelets through the process of aggregation. Activation of the coagulation cascade ultimately results in fibrin deposition. In pathological conditions, thrombogenic surfaces act as a nidus for platelet adherence and thrombus formation. The ability of platelet-inhibiting agents to prevent or impair platelet-mediated thrombotic and thromboembolic events is of vital importance in the prevention and treatment of cardiovascular diseases, including myocardial infarction, unstable angina and stroke. They also serve as important adjuvants following percutaneous transluminal coronary angioplasty and saphenous vein bypass grafting. Future investigations will likely uncover additional indications.
血管损伤发生后，血小板通过黏附于内皮下组织，然后通过聚集过程募集更多血小板，从而有助于正常止血。凝血级联反应的激活最终导致纤维蛋白沉积。在病理状态下，致血栓形成表面成为血小板黏附和血栓形成的病灶。血小板抑制剂预防或削弱血小板介导的血栓形成和血栓栓塞事件的能力，在预防和治疗心血管疾病（包括心肌梗死、不稳定型心绞痛和中风）中至关重要。它们在经皮腔内冠状动脉成形术和隐静脉搭桥术后也作为重要的辅助药物。未来的研究可能会发现更多的适应症。
